Literature DB >> 26906031

Poor standard mp-MRI and routine biopsy fail to precisely predict intraprostatic tumor localization.

Andrea Billing1, Alexander Buchner2, Christian Stief2, Alexander Roosen2.   

Abstract

PURPOSE: To evaluate the localization accuracy of routinely performed preoperative multiparametric MRI (mp-MRI), not being assessed according to PI-RADS criteria.
METHODS: One hundred and six patients underwent radical retropubic prostatectomy (January 2011-June 2012) with preoperative MRI. Intraprostatic tumor localization suggested by mp-MRI was correlated to both biopsy and histopathology results.
RESULTS: Sensitivity and specificity were as low as 25-62 and 60-94 %, respectively. Neither higher field force nor the use of an endorectal coil could enhance accuracy. There was no statistically significant concordance in any sextant. The mean number of correctly identified sextants was between 3.11 and 4.00 and, thus, insignificantly above the value of 3 that one would obtain by tossing the coin. For transrectal biopsies, sensitivity and specificity of tumor localization were 52-63 and 46-80 %, respectively.
CONCLUSIONS: Neither routinely performed "non-PI-RADS" MRI nor transrectal biopsy can accurately localize prostate cancer. Focal therapy concepts rely on a precise intraprostatic tumor detection and therefore inevitably require PI-RADS assessment by radiologists with genitourinary specialization. Regarding patient discomfort and costs, "non-PI-RADS" MRIs of the prostate are not justified.

Entities:  

Keywords:  Localization accuracy; Multiparametric MRI; Prostate cancer; Radical retropubic prostatectomy; Transrectal biopsy

Mesh:

Year:  2016        PMID: 26906031     DOI: 10.1007/s00345-016-1776-8

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  27 in total

Review 1.  Prostate cancer: multiparametric MR imaging for detection, localization, and staging.

Authors:  Caroline M A Hoeks; Jelle O Barentsz; Thomas Hambrock; Derya Yakar; Diederik M Somford; Stijn W T P J Heijmink; Tom W J Scheenen; Pieter C Vos; Henkjan Huisman; Inge M van Oort; J Alfred Witjes; Arend Heerschap; Jurgen J Fütterer
Journal:  Radiology       Date:  2011-10       Impact factor: 11.105

2.  Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.

Authors:  Maximilien C Goris Gbenou; Alexandre Peltier; Sanjai K Addla; Marc Lemort; Renaud Bollens; Denis Larsimont; Thierry Roumeguère; Claude C Schulman; Roland van Velthoven
Journal:  Urol Int       Date:  2011-10-15       Impact factor: 2.089

3.  Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy.

Authors:  E David Crawford; Shandra S Wilson; Kathleen C Torkko; Daisaku Hirano; J Scott Stewart; Craig Brammell; R Storey Wilson; Nozomu Kawata; Holly Sullivan; M Scott Lucia; Priya N Werahera
Journal:  BJU Int       Date:  2005-11       Impact factor: 5.588

4.  Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard.

Authors:  L Schimmöller; M Quentin; C Arsov; R S Lanzman; A Hiester; R Rabenalt; G Antoch; P Albers; D Blondin
Journal:  Eur Radiol       Date:  2013-06-12       Impact factor: 5.315

Review 5.  Advances in magnetic resonance imaging: how they are changing the management of prostate cancer.

Authors:  Alessandro Sciarra; Jelle Barentsz; Anders Bjartell; James Eastham; Hedvig Hricak; Valeria Panebianco; J Alfred Witjes
Journal:  Eur Urol       Date:  2011-02-23       Impact factor: 20.096

Review 6.  Focal therapy in prostate cancer: modalities, findings and future considerations.

Authors:  Uri Lindner; John Trachtenberg; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2010-09-14       Impact factor: 14.432

7.  Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer?

Authors:  Janice M Mayes; Vladimir Mouraviev; Leon Sun; Matvey Tsivian; John F Madden; Thomas J Polascik
Journal:  Urol Oncol       Date:  2009-05-17       Impact factor: 3.498

8.  Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.

Authors:  James E Thompson; Daniel Moses; Ron Shnier; Phillip Brenner; Warick Delprado; Lee Ponsky; Marley Pulbrook; Maret Böhm; Anne-Maree Haynes; Andrew Hayen; Phillip D Stricker
Journal:  J Urol       Date:  2014-02-08       Impact factor: 7.450

9.  Diffusion-weighted magnetic resonance imaging detects significant prostate cancer with high probability.

Authors:  Lauren J Bains; Urs E Studer; Johannes M Froehlich; Gianluca Giannarini; Maria Triantafyllou; Achim Fleischmann; Harriet C Thoeny
Journal:  J Urol       Date:  2014-03-15       Impact factor: 7.450

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  4 in total

1.  From novice to expert: analyzing the learning curve for MRI-transrectal ultrasonography fusion-guided transrectal prostate biopsy.

Authors:  R Mager; M P Brandt; H Borgmann; K M Gust; A Haferkamp; M Kurosch
Journal:  Int Urol Nephrol       Date:  2017-06-23       Impact factor: 2.370

2.  Contrast-enhanced ultrasound with dispersion analysis for the localization of prostate cancer: correlation with radical prostatectomy specimens.

Authors:  Arnoud W Postema; Maudy C W Gayet; Ruud J G van Sloun; Rogier R Wildeboer; Christophe K Mannaerts; C Dilara Savci-Heijink; Stefan G Schalk; Amir Kajtazovic; Henk van der Poel; Peter F A Mulders; Harrie P Beerlage; Massimo Mischi; Hessel Wijkstra
Journal:  World J Urol       Date:  2020-02-20       Impact factor: 4.226

3.  Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI.

Authors:  Raisa S Pompe; Bieke Kühn-Thomä; Yamini Nagaraj; Valia Veleva; Felix Preisser; Sami-Ramzi Leyh-Bannurah; Markus Graefen; Hartwig Huland; Derya Tilki; Georg Salomon
Journal:  World J Urol       Date:  2018-02-28       Impact factor: 4.226

Review 4.  Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer.

Authors:  Ryan Hutchinson; Yair Lotan
Journal:  Transl Androl Urol       Date:  2017-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.